Clinical Trial Update: Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating stereotactic body radiotherapy with or without darolutamide for oligorecurrent prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oligometastasis
• Prostate Cancer
• Prostate Cancer Recurrent

Drugs mentioned

• Darolutamide (darolutamide)

Snippet

Sponsor: University Hospital, Ghent | Conditions: Prostate Cancer, Prostate Cancer Recurrent | Phase 2 | Status: UNKNOWN